NCT06929182View on ClinicalTrials.gov

OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2035

Study Completion Date

July 1, 2035

Conditions
Antiphospholipid Syndrome (APS)Direct Oral Anticoagulants (DOACs)Thrombotic and Bleeding EventsSafety
Interventions
OTHER

"non-high risk thrombotic APS patients treated with DOAC"

There is no specific intervention in this study. Routine care data will be collected from patients with a 'non-high-risk' APS profile who are currently being treated with DOACs or have been in the past.

Trial Locations (1)

08035

Vall d´Hebron University Hospital, Barcelona

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER